East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. Aurobindo Pharma’s Desmopressin Acetate Tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), DDAVP Tablets manufactured by Ferring Pharmaceuticals, Inc.

Desmopressin Acetate Tablets are indicated as:

• Antidiuretic replacement therapy in the management of central diabetes insipidus
• Indicated for the management of primary nocturnal enuresis.